|19.98||-0.7500||-3.62%||Vol 83.01K||1Y Perf 149.94%|
|Oct 28th, 2020 10:25 DELAYED|
|- -%||- -%|
|Target Price||40.00||Analyst Rating||Strong Buy 1.00|
|Potential %||102.33||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||100/100/100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||100/100/100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/100||Income Ranking||— -|
|Market Cap||1.30B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||42.32||Earnings Date||3rd Nov 2020|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||3rd Nov 2020|
|Estimated EPS Next Report||0.35|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||420.56K|
|Avg. Monthly Volume||418.48K|
|Avg. Quarterly Volume||503.56K|
Arcus Biosciences Inc. (NYSE: RCUS) stock closed at 20.73 per share at the end of the most recent trading day (a 4.49% change compared to the prior day closing price) with a volume of 623.57K shares and market capitalization of 1.30B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 108 people. Arcus Biosciences Inc. CEO is Terry Rosen.
The one-year performance of Arcus Biosciences Inc. stock is 149.94%, while year-to-date (YTD) performance is 105.25%. RCUS stock has a five-year performance of %. Its 52-week range is between 7.19 and 37.41, which gives RCUS stock a 52-week price range ratio of 42.32%
Arcus Biosciences Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 3.05, a price-to-sale (PS) ratio of 98.66, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -31.03%, a ROC of -36.75% and a ROE of -35.75%. The company’s profit margin is -%, its EBITDA margin is -741.20%, and its revenue ttm is $13.25 Million , which makes it $0.20 revenue per share.
Of the last four earnings reports from Arcus Biosciences Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $0.35 for the next earnings report. Arcus Biosciences Inc.’s next earnings report date is 03rd Nov 2020.
The consensus rating of Wall Street analysts for Arcus Biosciences Inc. is Strong Buy (1), with a target price of $40, which is +102.33% compared to the current price. The earnings rating for Arcus Biosciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Arcus Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Arcus Biosciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 12.78, ATR14 : 1.16, CCI20 : 90.35, Chaikin Money Flow : 0.16, MACD : 0.04, Money Flow Index : 59.97, ROC : 6.14, RSI : 55.54, STOCH (14,3) : 84.09, STOCH RSI : 1.00, UO : 55.46, Williams %R : -15.91), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Arcus Biosciences Inc. in the last 12-months were: Robert C. Goeltz (Buy at a value of $107 849), Terry Rosen (Buy at a value of $999 314), William Grossman (Buy at a value of $1 968), Yasunori Kaneko (Option Excercise at a value of $559 300)
Copyright (c) 2020. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.